Friday, March 31, 2023
Clinical Advances in
Recent developments in insulin therapy focusing on new formulations or routes of administration and the evolving usage of continuous glucose monitoring (CGM) have opened new frontiers in the management of both type 1 and type 2 diabetes mellitus (T1DM and T2DM). While novel faster- or longer-acting insulins are expanding the options in diabetes management, the ever-growing integration of CGM in clinical practice is also contributing to the transformation of diabetes care over the last decade. In this program, key opinion leaders in diabetes from across the globe will take the audience on a journey to these new frontiers in diabetes care.
Supported by an independent educational grant from Novo Nordisk A/S
Steering Committee Chair
Professor of Medicine
Katholieke Universiteit Leuven
Head of Endocrinology
University Hospital Gasthuisberg
Leuven, Belgium
Professor of Pediatrics
Chief Physician
Department of General Pediatrics, Endocrinology and Diabetes
Children's Hospital "Auf der Bult“
Hannover, Germany
Professor of Internal Medicine
University of Amsterdam
Amsterdam, the Netherlands
Medical Director
Profil
Neuss, Germany
Assistant Medical Director
Research & Development
Swansea Bay University Health Board
Clinical Director
Diabetes Research Unit Swansea Bay University Medical School
Swansea, United Kingdom
Consultant and Head of Department of Pediatric and Adolescent Endocrinology
UMC Ljubljana
Head, Chair of Pediatrics, and Professor of Pediatrics
Faculty of Medicine
University of Ljubljana
Ljubljana, Slovenia
Corporate Vice President
Scripps Health (Scripps Whittier Diabetes Institute)
San Diego, California, United States
Steering Committee Chair
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: NovoNordisk, Sanofi, Merck Sharp and Dohme Ltd., Eli Lilly and Company, Novartis, AstraZeneca, Boehringer Ingelheim, Hanmi Pharmaceuticals, Roche, Medtronic, ActoBio Therapeutics, Pizer and UCB.
Served as a speaker or a member of a speakers bureau for: Novo Nordisk, Sanofi, Merck Sharp and Dohme, Eli Lilly and Company, Boehringer Ingelheim, AstraZeneca and Novartis.
Other: KU Leuven
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Diabetes Care Inc., AstraZeneca, Novo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim GmbH, Lexicon Pharmaceuticals, Inc., Medtronic MiniMed, Sanofi
Served as a speaker or a member of a speakers bureau for: Abbott Diabetes Care Inc., AstraZeneca, Novo Nordisk A/S, Eli Lilly and Company, DexCom., Medtronic MiniMed, Sanofi
Received grants for clinical research from: Abbott Diabetes Care Inc., AstraZeneca, Novo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim GmbH, Lexicon Pharmaceuticals, Inc., Medtronic MiniMed
Owns stock, stock options, or bonds from: DreaMed Ltd
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Novo Nordisk
Served as a speaker or a member of a speakers bureau for: Novo Nordisk
Other: Employed by a commercial interest: Profil Institute for Metabolic Research
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Novo Nordisk, Merck Sharp and Dohme
Served as a speaker or a member of a speakers bureau for: Eli Lilly; Novo Nordisk; Sanofi
Received grants for clinical research from: Novo Nordisk; Sanofi
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eli Lilly; Sanofi; Medtronic; Novo Nordisk; Indigo
Served as a speaker or a member of a speakers bureau for: Eli Lilly; Sanofi; Novo Nordisk; Medtronic; Abbott Diabetes; Dexcom
Received grants for clinical research from: NIH-NIDDK; EU Commission; Slovenian Research Agency; Novo Nordisk; Sanofi; Medtronic
Owns stock, stock options, or bonds from: DreaMed Diabetes
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Sanofi; Novo Nordisk; Eli Lilly
Received grants for clinical research from: Jansen; Novo Nordisk; Sanofi; Eli Lilly